Vexas Discovery

Over $100,000

VEXAS, a novel autoimmune disease, could hold the key to discovering a biomarker for RP.

Collaborating to Find a Biomarker for RP

Relapsing polychondritis (RP) and VEXAS syndrome are both adult-onset inflammatory autoimmune conditions. We are collaborating with the clinical researchers at The University of Texas MD Anderson Cancer Center and NYU Grossman School of Medicine who discovered VEXAS to continue the search for additional genetic mutations in patients with RP-related autoimmune diseases and bring science closer to the discovery of a biomarker for RP.

Advancing VEXAS Research

We’ve provided over $100,000 in funding for the next phase of VEXAS research. The goal of this phase is to continue the search for additional genetic mutations in patients with autoimmune diseases and bring science closer to the discovery of a biomarker for RP. This project will leverage a collaborative network of talented researchers in the Inflammatory Disease Genetics Program at NYU Langone in the Center for Human Genetics and Genomics and Division of Rheumatology and the Relapsing Polychondritis and Autoinflammatory Clinics at the NIH.

“We are confident that Drs. Kanagal-Shamanna and Beck’s collaborative study will generate a greater understanding of RP and MDS”

- David Bammert, RP Foundation President

Results of VEXAS Research

The VEXAS research program is ongoing. We’ll be sure to update this section once it is complete. Learn more about VEXAS and the research we’re supporting here:

Result: Year’s best in discovery at the American Society of Hematology: https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V19.1.2022117/483395/This-Year-s-Best-in-Hematology-Diagnosis-A-New

Result: UBA1 mutations as a frequent driver of Relapsing Polychondritis: https://pubmed.ncbi.nlm.nih.gov/33779074/

Result: UBA1 mutations as a cause of Lupus: https://pubmed.ncbi.nlm.nih.gov/34463053/

For more information about VEXAS Syndrome visit:

VEXAS.org

Where There’s Research, There’s Hope

Until recently, there were few options and even fewer resources for patients living with RP. We’re working every day to unlock the mysteries of RP and deliver hope to patients and their families.